$118.84
2.74% today
Nasdaq, Feb 28, 05:18 pm CET
ISIN
US53220K5048
Symbol
LGND

Ligand Pharmaceuticals Incorporated Stock price

$115.67
-1.61 1.37% 1M
+9.34 8.78% 6M
+8.52 7.95% YTD
+26.47 29.67% 1Y
+53.94 87.38% 3Y
+52.64 83.50% 5Y
+82.09 244.41% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.66 0.57%
ISIN
US53220K5048
Symbol
LGND
Sector
Industry

Key metrics

Market capitalization $2.19b
Enterprise Value $1.97b
P/E (TTM) P/E ratio 46.02
EV/FCF (TTM) EV/FCF 26.72
EV/Sales (TTM) EV/Sales 12.95
P/S ratio (TTM) P/S ratio 14.34
P/B ratio (TTM) P/B ratio 2.58
Revenue growth (TTM) Revenue growth -0.76%
Revenue (TTM) Revenue $152.42m
EBIT (operating result TTM) EBIT $17.98m
Free Cash Flow (TTM) Free Cash Flow $73.86m
Cash position $219.64m
EPS (TTM) EPS $2.51
P/E forward 66.22
P/S forward 13.30
EV/Sales forward 12.00
Short interest 6.97%
Show more

Is Ligand Pharmaceuticals Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Ligand Pharmaceuticals Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:

Buy
100%

Financial data from Ligand Pharmaceuticals Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
152 152
1% 1%
100%
- Direct Costs 43 43
32% 32%
28%
110 110
21% 21%
72%
- Selling and Administrative Expenses 31 31
5% 5%
21%
- Research and Development Expense 23 23
23% 23%
15%
56 56
79% 79%
36%
- Depreciation and Amortization 38 38
1% 1%
25%
EBIT (Operating Income) EBIT 18 18
360% 360%
12%
Net Profit 45 45
175% 175%
30%

In millions USD.

Don't miss a Thing! We will send you all news about Ligand Pharmaceuticals Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ligand Pharmaceuticals Incorporated Stock News

Neutral
Seeking Alpha
about 21 hours ago
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysis Todd Davis - CEO Paul Hadden - Senior Vice President of Investments and Business Development Tavo Espinoza - Chief Financial Officer Lauren Hay - Vice President of Strategic Planning and Investme...
Neutral
GlobeNewsWire
one day ago
Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share 1 of $6.00-$6.25 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla.
Neutral
GlobeNewsWire
3 days ago
Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors invested $25 million in return for a high-single digit royalty on D-Fi JUPITER, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has cl...
More Ligand Pharmaceuticals Incorporated News

Company Profile

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Head office United States
CEO Todd Davis
Employees 58
Founded 1987
Website www.ligand.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today